Navigation Links
Frost & Sullivan Recognizes GenePOC's Growth Backed by Strong Leadership and Technology Excellence
Date:2/25/2013

MOUNTAIN VIEW, Calif., Feb. 25, 2013 /PRNewswire/ -- Based on its recent analysis of the molecular diagnostics market, Frost & Sullivan recognizes GenePOC, Inc. with the 2013 North America Frost & Sullivan Entrepreneurial Company of the Year Award. The company's biggest strengths are its technology and leadership. GenePOC has completed its first step in growth implementation by demonstrating its superior molecular technology. Its next goal is to expand the usage of its system at the point of care to optimize patient management and target therapies.

The company stands out in the molecular diagnostics market due to its product and technology innovation. It addresses point-of-care testing needs with a fully-automated, standalone, and plug-and-play system that provides quick results. The system has a universal sample preparation method and can handle numerous sample types, including nasal, vaginal and throat swabs.

"GenePOC's technology employs real-time polymerase chain reaction, microfluidics, microfabrication, biomarkers and bioinformatics, enabling physicians to diagnose diseases more rapidly," said Frost & Sullivan Global Program Manager Jennifer Brice . "While other vendors have attempted to cater to the POC testing market with molecular diagnostics platforms, GenePOC's system is uniquely designed to be user-friendly."

GenePOC has a well-delineated strategy to obtain funding in 2013, accelerate development in 2013 and then launch its technology in Europe in 2014, since the European market is more flexible than the U.S. market. GenePOC aims to have four or five tests in Europe by 2015, before it can launch its platforms in the U.S.

GenePOC's technology can fully automate molecular diagnostic testing at the point of care and provide results in less than an hour, and with less than 3 minutes of hands-on time. Its molecular diagnostics system can process a broad range of sample types; it can test eight different samples simultaneously during a single run, with up to 12 targets per sample. This is an attractive feature, especially considering that both the instrument and consumables are cost-effective and easy to use.

The GenePOC system's protocols are the same for all tests, even for those with different targets and different samples. Moreover, the volume capacity of GenePOC's system exceeds that of other systems.

Unlike other systems, GenePOC's system does not produce significant amounts of waste; it produces approximately 10 percent of the waste of other devices, in terms of both volume and weight. As the system does not require purification and amplification of sample DNA, it offers enhanced ease of use and efficiency.

"GenePOC aims to transform the market by responding to customers' demand for a simple, user-friendly molecular diagnostic system," noted Brice. "It continues to find ways to improve its methods in order to produce affordable and, therefore, viable molecular diagnostic test consumables."

Each year, Frost & Sullivan presents this award to the company that has demonstrated entrepreneurial spirit by devising a strong growth strategy and robustly implementing it. The recipient has shown strength in terms of innovation in business processes, leadership in customer value as well as market penetration. In short, the award looks at the emerging market players in the industry and recognizes their best practices that are positioned for future growth excellence.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About GenePOC, Inc.

Created in 2007 and located in Quebec city, Canada, GenePOC, Inc. is a privately owned company that develops rapid and cost-effective molecular tests to detect genes at Point of Care (POC).

Since the PCR has been invented in the mid 80's, GenePOC founder, Dr. Michel G. Bergeron , had the goal of using DNA to speed up the identification of microbes to one hour or less instead of more than 48 hours with standard culture. For more information visit http://www.genepoc-diagnostics.com/Home.shtml

GenePOC Contact: 


Dr. Patrice Allibert , Ph.D., CEO,
P: +1 418 570 3611
E: patrice.allibert@genepoc.ca
www.genepoc-diagnostics.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation

Contact:

Mireya Espinoza
P: 210.247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Accolade for Swissrays Exceptional Dedication to its Customers
2. Novel Biomaterials Accelerate the Development of Innovative Wound Care Management Technologies, Finds Frost & Sullivan
3. Frost & Sullivan: Clinical Trial-based Evidence Vital to Obtain Venture Capital Funding for Wireless Patient Monitoring Technologies
4. Frost & Sullivan Acknowledges that PKCs Biosensors are Expected to Become the New Industry Standard in Pathogen Testing
5. Increasing Surgical Volumes to Boost Use of Tissue Sealants and Topical Haemostats, Says Frost & Sullivan
6. Frost & Sullivan: Digitisation of Australias healthcare system met with widespread apprehension
7. Frost & Sullivan Recognizes ResearchDx for Its Impressive Performance in the Companion Diagnostics Sector
8. Gains from a Growing Patient Pool for Cardiac Rhythm Management Devices Offset by Lower Product Pricing, Observes Frost & Sullivan
9. Frost & Sullivan Determines a Real and Urgent Need for Novel Cancer Diagnostics Tests
10. Best Practices Involving Product Innovation and Creation of Value Vital for Customer Retention, Finds Frost & Sullivan
11. Contract Research Organisations offer Promise of Innovative, Safe and Effective Drug Development, Says Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ANKENY, Iowa , 11 de fevereiro de ... a inauguração de sua fábrica de soroalbumina bovina ... Nova Zelândia. A fábrica fica na Ilha Norte ... Loop "), desenvolvido e estabelecido na fábrica da ... Iowa . O projeto e instalação dos ...
(Date:2/11/2016)... 2016 Breast Cancer Therapeutics in Asia-Pacific ... Asia-Pacific (APAC) breast cancer market will experience considerable ... 2021, at a Compound Annual Growth Rate (CAGR) of 8.5%. ... 2021 - states that the Asia-Pacific ... $1.9 billion in 2014 to $3.4 billion by 2021, at ...
(Date:2/11/2016)... , February 11, 2016 Jeffrey ... Worldwide Clinical Trials, will present at this year,s Summit for ... Hyatt Regency in Miami, FL. Zucker ... to optimize study execution, supporting SCOPE,s "Improving Site Study Activation ... place on Thursday, Feb. 25 at 11:05 a.m. ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 11, 2016 , ... Student-doctors from Western University of Health ... Tuesday, February 9, taking one of the final steps in their medical school ... across the country. Of the 103 student-doctors who comprise the College of Osteopathic ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Image ... business to a new market, and it’s the buildings of Nashville that will benefit. ... when I needed to relocate to Nashville, there was no question that I would ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... and women’s health, is pleased to announce the promotions of Allison Kelly to ... team, Steve Catone to executive vice president of North American capital sales, and ...
(Date:2/11/2016)... Australia (PRWEB) , ... February 11, 2016 , ... ... potential ?" motivational speaker, trainer and author Ray Clarke poses a question as ... personal fulfillment . In his book, "Being in the Being" (published by Partridge ...
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
Breaking Medicine News(10 mins):